Core Insights - The skincare industry is experiencing intense competition in technology, with numerous suppliers showcasing unique ingredients and certifications at a recent cosmetics trade show [1][2][3] - The trend of emphasizing active ingredients and technical claims on product packaging is prevalent, as brands seek to carve out market positions by replicating successful commercial models [4][5] - The lack of authoritative industry standards and clarity on ingredient efficacy is causing confusion and skepticism among consumers [6][7][8] Group 1: Active Ingredients and Technology Trends - Active proteins and plant extracts remain core competitive areas in the skincare industry, with leading brands continuing to invest heavily in research and development [10][11] - The popularity of active proteins is driven by their previous applications in medical and aesthetic fields, which lend credibility to their use in consumer products [15][20] - New technologies in plant extraction are emerging, aiming to address traditional challenges such as stability and absorption rates [18][19] Group 2: Marketing and Industry Challenges - The rapid iteration of core ingredients in domestic beauty brands has outpaced normal industry evolution, leading to communication gaps between technology, products, and consumers [22][23] - The absence of unified national standards for new ingredients has resulted in market confusion and potential harm to consumers [24][26] - Overemphasis on marketing claims has led to exaggerated efficacy narratives, causing consumer dissatisfaction and adverse reactions [30][31][33] Group 3: Future Directions and Brand Strategies - The skincare industry is entering a period of deep adjustment, with competition shifting from ingredient-based to ecosystem-building capabilities [37][39] - Brands must find new competitive advantages beyond ingredient efficacy, such as emotional value and consumer experience [41][42] - The rise of niche markets, including male skincare and elderly care, presents new opportunities for growth and diversification [48][49]

Group 1 - The establishment of Huaxi Tang'an Bio-Tech in Guangming marks a significant strategic deployment for Huaxi Bio, expanding its diversification beyond hyaluronic acid and establishing a global non-animal heparin full industry chain platform in the Guangdong-Hong Kong-Macao Greater Bay Area [2] - Huaxi Bio focuses on synthetic biology, with four main business segments: bioactive raw materials, pharmaceuticals and medical devices, skin science innovation, and nutritional science innovation, featuring brands such as Runzhi, Runbaiyan, Kuadi, Mibeier, and BM Jihuo [2] - Huaxi Tang'an has achieved multi-dimensional technological breakthroughs in the field of fully enzymatic synthesis of heparin, with applications in cosmetics, pharmaceuticals, and medical devices, serving as key drugs for the prevention and treatment of thromboembolic diseases, myocardial infarction, and anticoagulation in cardiovascular surgeries [2] Group 2 - The signing ceremony included agreements with Guangming District, the National Bio-Manufacturing Industry Innovation Center, and Xingbo Shenghui Private Venture Capital Fund for landing and angel round financing [3] - A roundtable forum titled "Synthetic Biology Empowering Heparin Industry Transformation" was held with key figures from academia and industry, including Zhang Xian'en, Guo Xueping, Ma Yingfei, Gu Zheyi, and Fang Xing [3] Group 3 - Guangming District has gathered over 130 enterprises in the synthetic biology field, with an estimated industry valuation of nearly 40 billion [4]

Group 1 - Morning Light Biological expects a net profit of 202.0 million to 232.0 million yuan for the first half of 2025, representing a year-on-year increase of 102.33% to 132.38% [1] - Northern Rare Earth anticipates a net profit of 900.0 million to 960.0 million yuan for the first half of 2025, with a significant year-on-year growth of 1882.54% to 2014.71% [1] - Youfa Group forecasts a net profit of 277.0 million to 307.0 million yuan for the first half of 2025, reflecting a year-on-year increase of 151.69% to 178.93% [1] Group 2 - Torch Electronics projects a net profit of approximately 247.0 million to 280.0 million yuan for the first half of 2025, indicating a year-on-year growth of 50.36% to 70.45% [3] - Zhiwei Intelligent expects a net profit of 91.98 million to 112.43 million yuan for the first half of 2025, with a year-on-year increase of 62.85% to 99.06% [4] - Youhao Group anticipates a net profit of 12.0 million yuan for the first half of 2025, representing a year-on-year growth of 51% [5] Group 3 - Nami Technology expects a net profit of 61.0 million to 73.0 million yuan for the first half of 2025, with a year-on-year increase of 35% to 62% [7] - Xinda Co. forecasts a net profit of 130.0 million to 150.0 million yuan for the first half of 2025, reflecting a substantial year-on-year growth of 2443.43% to 2834.73% [8] Group 4 - Shaanxi Coal Industry reported a coal production of 14.36 million tons in June, a year-on-year decrease of 5.07% [9] - Huanxu Electronics announced a consolidated revenue of 4.587 billion yuan in June, a year-on-year decline of 1.23% [10] Group 5 - Huadian International successfully issued 2.0 billion yuan in medium-term notes with a maturity of 3+N years and a coupon rate of 1.89% [20] - Zhongmin Energy reported a total power generation of 1.405 billion kilowatt-hours in the first half of 2025, a year-on-year decrease of 0.89% [20] Group 6 - Huaxia Biotech passed the FDA inspection with zero deficiencies, covering six major systems [21] - Ruikeda's application for convertible bond issuance has been accepted by the Shanghai Stock Exchange [22] Group 7 - Dafu Technology plans to invest no more than 100 million yuan in Anhui Yunta [42] - Tongda Co. won a bid for a project valued at 180.3 million yuan from the Southern Power Grid [46]

证券代码：688363 证券简称：华熙生物 公告编号：2025-026 此次是公司继 2012 年首次参与美国 FDA 现场检查以来，第五次通过 FDA 现场检查，表明公司高质量生产制造规范持续获得国际权威机构的认可。本次"零 缺陷通过"为 FDA 对药品生产质量体系合规性的最高认可，标志着公司质量管 理体系达到国际高标准。该质量体系为公司产品满足国际法规要求提供可靠支持， 有助于增强全球合作伙伴对公司产品合规性与质量的信心，为拓展国际市场创造 有利条件，进一步提升公司国际竞争力，对公司未来发展产生积极影响。 由于医药行业特点，原料药产品生产、销售受到行业政策、市场环境、供求 关系等因素影响，具有一定的不确定性。敬请广大投资者理性决策，注意投资风 险。 特此公告。 华熙生物科技股份有限公司董事会 2025 年 7 月 10 日 1 华熙生物科技股份有限公司 关于自愿披露公司通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2025 年 3 月 ...

Core Viewpoint - The company successfully passed the FDA's cGMP inspection with zero deficiencies, indicating high standards in its quality management system and manufacturing practices [1] Group 1: FDA Inspection Details - The FDA conducted a cGMP inspection from March 24 to March 28, 2025, covering six major systems: quality system, facilities and equipment, material system, production system, laboratory system, and packaging and labeling [1] - The inspection focused on the sodium hyaluronate active pharmaceutical ingredient [1] Group 2: Company Recognition - This marks the fifth time the company has passed an FDA inspection since its first participation in 2012, demonstrating consistent recognition from international regulatory authorities [1] - Achieving a "zero deficiency" status is the highest recognition from the FDA regarding compliance with drug production quality systems, signifying that the company's quality management system meets international high standards [1]

Core Viewpoint - The establishment of Huaxi Tang'an Bio-Tech in Guangming Science City marks a significant strategic deployment for Huaxi Bio, expanding its diversification beyond hyaluronic acid and establishing a global non-animal heparin full industry chain platform in the Guangdong-Hong Kong-Macao Greater Bay Area [1][3]. Group 1: Company Development - Huaxi Bio focuses on synthetic biology, emphasizing glycomics and cell biology, and has developed four major business segments: bioactive raw materials, pharmaceuticals and medical devices, skin science innovation, and nutritional science innovation [1]. - Huaxi Tang'an has achieved multi-dimensional technological breakthroughs in the field of enzyme-synthesized heparin, with applications in cosmetics, pharmaceuticals, and medical devices, particularly in preventing and treating thromboembolic diseases and cardiovascular surgeries [1][3]. Group 2: Industry Collaboration and Ecosystem - The signing ceremony involved partnerships with Guangming District, the National Bio-Manufacturing Industry Innovation Center, and private equity funds, leveraging policy and resource advantages to accelerate project development [3]. - Guangming District has attracted over 130 companies in the synthetic biology sector, with an estimated industry valuation of nearly 40 billion, establishing a comprehensive innovation ecosystem covering research, technology development, and talent support [3][4]. Group 3: Future Prospects - The establishment of Huaxi Tang'an is expected to attract more upstream and downstream enterprises in the medical beauty and cosmetics sectors, contributing to the creation of a distinctive industrial cluster in Guangming [4].

Core Viewpoint - The legal opinion issued by Tongshang Law Firm confirms that Huaxi Biological Technology Co., Ltd.'s differentiated dividend distribution plan for 2024 complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [3][6]. Group 1: Differentiated Dividend Distribution - The reason for the differentiated dividend distribution is due to the company's share repurchase plan, which will result in a discrepancy between the total share capital and the shares participating in profit distribution [3][4]. - Huaxi Biological plans to distribute a cash dividend of RMB 0.11 per share (tax included) based on the total share capital minus the shares held in the repurchase account, with no capital reserve conversion or bonus shares [4][5]. - As of the date of the legal opinion, the total share capital of Huaxi Biological is 481,678,242 shares, with 3,315,538 shares in the repurchase account, leading to a total of 478,362,704 shares eligible for the cash dividend distribution, amounting to a total of RMB 52,619,897.44 (tax included) [5]. Group 2: Calculation Basis for Dividend Distribution - The calculation for the ex-dividend reference price is based on the formula: (previous closing price - cash dividend) ÷ (1 + change in circulating shares ratio), with the circulating shares ratio being 0 since only cash dividends are distributed [5]. - The closing price of the stock on June 23, 2025, was RMB 50.67 per share, leading to an ex-dividend reference price of RMB 50.56 per share after accounting for the cash dividend [5][6]. - The impact of the differentiated dividend on the ex-dividend reference price is less than 1%, indicating a minimal effect [6]. Group 3: Legal Compliance and Conclusion - The legal opinion asserts that the differentiated dividend distribution does not violate the Company Law, Securities Law, or self-regulatory guidelines, and does not harm the interests of the company or its shareholders [6].

Core Viewpoint - The company has announced a differentiated dividend distribution plan, with a cash dividend of RMB 0.11 per share (tax included) for the 2024 fiscal year, approved at the annual shareholders' meeting on June 11, 2025 [1][2]. Dividend Distribution Plan - The total share capital, excluding shares in the company's repurchase account, is 481,678,242 shares, with 3,315,538 shares in the repurchase account, resulting in 478,362,704 shares eligible for the dividend distribution [2]. - The cash dividend distribution will not involve capital reserve conversion to share capital or the issuance of bonus shares [1][2]. - The reference price for the ex-dividend (ex-rights) calculation is determined by the formula: (previous closing price - cash dividend) / (1 + change in circulating shares ratio) [2]. Tax Implications - For individual shareholders and securities investment funds, dividends are subject to different tax treatments based on the holding period. If held for over one year, dividends are exempt from individual income tax. For holdings of one year or less, tax will be calculated upon the sale of shares [3][4]. - Qualified Foreign Institutional Investors (QFIIs) will have a 10% corporate income tax withheld on dividends, resulting in a net cash dividend of RMB 0.099 per share [4]. - For Hong Kong investors holding shares through the "Shanghai-Hong Kong Stock Connect," a 10% withholding tax will also apply, leading to a net cash dividend of RMB 0.099 per share [4]. Implementation Details - Cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited Shanghai Branch, with specific arrangements for different types of shareholders [3][5]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the trading is completed [3].

中国北京建国门外大街 1 号国贸写字楼 2 座 12-15 层 100004 12-15th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于华熙生物科技股份有限公司 差异化分红事项之专项法律意见书 的陈述应是完整、真实、准确和有效的，并无隐瞒、虚假或重大遗漏之处；签 署文件的主体均应具有签署文件的权利能力和行为能力，所提供文件中的所有 签字和印章均是真实的；文件材料为副本或复印件的，应与正本或原件是一致 和相符；一切足以影响本法律意见书的事实和文件均应向本所披露，而无任何 隐瞒、遗漏、虚假或误导之处；该等事实和文件于提供给本所之日至本法律意 见书出具之日，未发生任何变更； 3、对出具本法律意见书至关重要而又无法得到独立的证据支持的事实，本 所依赖政府有关部门、公 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-025 华熙生物科技股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/11 | 2025/7/14 | 2025/7/14 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 11 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的除华熙生物科技 股份有限公司回购专用证券账户外的本公司全体股东。 3. 差异化分红送转方案： （1） 差异化分红送转方案 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年度利润分配预 由于公司本次进行差异化分红送转，上述公式中现金 ...